Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors

Renal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard‐of‐care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Nephrology (Carlton, Vic.) Vic.), 2021-02, Vol.26 (2), p.105-118
Hauptverfasser:	Yap, Desmond Y. H., McMahon, Lawrence P., Hao, Chuan‐Ming, Hu, Nan, Okada, Hirokazu, Suzuki, Yusuke, Kim, Sung Gyun, Lim, Soo Kun, Vareesangthip, Kriengsak, Hung, Chi‐Chih, Nangaku, Masaomi
Format:	Artikel
Sprache:	eng
Schlagworte:	anaemia Anemia Asian Pacific chronic kidney disease Erythropoietin Hydroxylase Hypoxia hypoxia inducible factor Kidney diseases Nephrology Patients Prolyl hydroxylase prolyl hydroxylase inhibitor Review Reviews
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!